

To: Riley, Karen <Karen.Riley@fda.hhs.gov>
Subject: FW: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Here you go...

From: Duarte, Christina
Sent: Friday, May 29, 2020 12:00 PM
To: Riley, Karen <Karen.Riley@fda.hhs.gov>
Subject: FW: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Hi Karen,

When time permits, can you please review the attached correspondences and information contained in the AIMS email below? Please let me know the POC to send this to.

Thank you,

Christina Duarte

Management and Program Analyst
Communications Team
Office of Global Diplomacy and Partnerships (OGDP)
Office of Global Policy and Strategy
U.S. Food and Drug Administration
(240) 402-5338 (phone)
Christina.Duarte@fda.hhs.gov

From: aimssystem@fda.hhs.gov <aimssystem@fda.hhs.gov>
Sent: Friday, May 29, 2020 11:24 AM
To: Duarte, Christina <Christina.Duarte@fda.hhs.gov>
Subject: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Note: Do NOT reply directly to this E-mail

A referral has been sent to your office by FDA/OC/OES/ on Correspondence Control # 2020-2504 requesting your assistance. A summary of the referral appears below. If you have any questions, please contact VALERIE A. JACKSON WATSON of FDA/OC/OES/.

Action: **Review and Clear**
Due Date: **Tuesday, June 2, 2020**
Synopsis: **Department R/C - Request for Access to Wuhan for International Scientists and Public Health Experts**

Please click the URL below to access the referral:

http://aims.fda.gov/cktoken/ct_token.mainPage?p_token=nrtd6ce3w03d68g9s1z00000vem3vx00001mbksjacetw8324196doqt1z0fnsxs

You can view the original correspondence by clicking the button 'View Orig Corr' (if available). After reviewing all the information provided, please acknowledge receipt of the referral by clicking either the ACCEPT button or the DECLINE button.

If you ACCEPT the referral, a new COMPLETE button is immediately displayed. You can either:

Click the COMPLETE button to complete the referral now

OR

You MUST retain this e-mail with the above URL until you have completed the referral request. Click the above URL again and click the COMPLETE button.

From: McNeill, Lorrie [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=77B0B352C9C24851BF0C7330F53E00D9-MCNEILL]
Sent: 6/2/2020 12:32:36 PM
To: Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]
CC: Tierney, Julia [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1160d300bc4248b790ded292a082e9a8-Julia.Tiern]
Subject: FW: See this instead
Attachments: Control Sheet - 00437348-AS-857907.docx; Agnew WIV letter - clean -OGA.docx; Kenna-Agnew memo 202005717.pdf

Hi Peter –

Karen Riley in OGDG shared the email string below and attachments regarding a letter to the Department of State declining to co-sign a letter to the PRC. The attached draft response notes that HHS has already sent a letter to the Secretary's counterpart and therefore do not want to "confuse issues" by joining this letter.

After Karen sent, she sent a separate note that Mark Abdoo has cleared the draft and at this point it's an FYI only for us (despite the note below that you should review).

Lorrie

From: Riley, Karen <Karen.Riley@fda.hhs.gov>
Sent: Tuesday, June 2, 2020 11:07 AM
To: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Subject: See this instead

Hi Lorrie, Somehow the email didn't finish. FDA has been asked to weigh in on an HHS/OGA letter to State declining to sign onto a letter to the Wuhan Institute of Virology. We're thinking that Peter should review. Thanks.

From: Riley, Karen
Sent: Tuesday, June 2, 2020 11:05 AM
To: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Subject: Please see

Hi Lorrie, FDA has been asked to weigh in in an HHS/OGA letter to State declining to sign onto a partiWe

From: Riley, Karen
Sent: Tuesday, June 2, 2020 10:37 AM
To: Hashemi, Sema <Sema.Hashemi@fda.hhs.gov>; Ross, Bruce <Bruce.Ross@fda.hhs.gov>; Anderson, Erika <Erika.Anderson@fda.hhs.gov>
Subject: Please see

I believe I forwarded this to some of you on Friday. My apologies, I misinterpreted this. I thought it was an FYI, but apparently we are being asked to clear the Agnew letter back to State. Should Janet Woodcock also read and clear?

From: Duarte, Christina <Christina.Duarte@fda.hhs.gov>
Sent: Friday, May 29, 2020 12:49 PM
To: Riley, Karen <Karen.Riley@fda.hhs.gov>
Subject: FW: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Here you go...

From: Duarte, Christina
Sent: Friday, May 29, 2020 12:00 PM
To: Riley, Karen <Karen.Riley@fda.hhs.gov>
Subject: FW: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Hi Karen,

When time permits, can you please review the attached correspondences and information contained in the AIMS email below? Please let me know the POC to send this to.

Thank you,

Christina Duarte

Management and Program Analyst
Communications Team
Office of Global Diplomacy and Partnerships (OGDP)
Office of Global Policy and Strategy
U.S. Food and Drug Administration
(240) 402-5338 (phone)
Christina.Duarte@fda.hhs.gov

From: aimssystem@fda.hhs.gov <aimssystem@fda.hhs.gov>
Sent: Friday, May 29, 2020 11:24 AM
To: Duarte, Christina <Christina.Duarte@fda.hhs.gov>
Subject: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Note: Do NOT reply directly to this E-mail

A referral has been sent to your office by FDA/OC/OES/ on Correspondence Control # 2020-2504 requesting your assistance. A summary of the referral appears below. If you have any questions, please contact VALERIE A. JACKSON WATSON of FDA/OC/OES/.

Action:
Due Date:
Synopsis:

Review and Clear
Tuesday, June 2, 2020
Department R/C -
Request for Access to
Wuhan for International
Scientists and Public
Health Experts

Please click the URL below to access the referral:

http://aims.fda.gov/cktoken/ct_token.mainPage?p_token=nrtd6ce3w03d68g9s1z00000vem3vx00001mbksjacetw8324196doqt1z0fnsxs

You can view the original correspondence by clicking the button 'View Orig Corr' (if available). After reviewing all the information provided, please acknowledge receipt of the referral by clicking either the ACCEPT button or the DECLINE button.

If you ACCEPT the referral, a new COMPLETE button is immediately displayed. You can either:

Click the COMPLETE button to complete the referral now

OR

You MUST retain this e-mail with the above URL until you have completed the referral request. Click the above URL again and click the COMPLETE button.



CONTROL SHEET CORRESPONDENCE

DATE: 05/28/2020

OVERVIEW

SPS#: 00437348
TYPE: Other Government
SUBJECT: (SBU) Request for Access to Wuhan for International Scientists and Public Health Experts
AUTHORING AGENCY: Office of Global Affairs (OGA)
POLICY COORDINATOR: Ekaterini (Kat) Malliou, (202) (b)(6)
ODRM ANALYST: Elaine Gross, (202) (b)(6)

ASSIGNMENT

TASK TYPE: Clearance Request
ACTION REQUIRED: Clearance
ROUND #: 1
DUE DATE: 06/02/2020 6:00 PM
RECIPIENTS: ASFR, ASL, ASPA, ASPR, CDC, Danielle Steele, FDA, NIH, OASH, OGC, Paula Stannard
INFO COPY:

INSTRUCTIONS:

Lisa D. Kenna
Executive Secretary
Department of State

Dear Ms. Kenna:

Thank you for the invitation to U.S. Department of Health and Human Services (HHS) Secretary Alex Azar to co-sign a letter to the People's Republic of China (PRC) Vice Premier Han Zheng and Yang Jiechi, Director of the Office of Foreign Affairs of the Communist Party of China regarding the Wuhan Institute of Virology. After careful consideration, HHS respectfully declines to join the letter. As you may know, we have sent our own letter to Mr. Azar's counterpart at the National Health Commission, Minister Ma Xiaowei, regarding sample sharing. We would like to ensure that line of inquiry remains open, and as such do not wish to confuse issues by joining this letter. Further, we recently ended funding to the institute that this letter is requesting access to. A request for a visit could be construed as opening the possibility for that funding to again be available, something we do not wish to be suggested.

HHS recommends that the State Department reconsider sending the letter as it could be used to curtail access to Chinese vaccine and therapeutic development – something that we also do not wish to do as it could impede other Presidential health initiatives, such as Operation Warp Speed. Finally, the letter is now overtaken by the resolution agreed to at the 73rd World Health Assembly sponsored by more than 130 countries, including the United States, mandating WHO, working with the Food and Agricultural Organization and the World Organization for Animal Health to undertake an investigation into the origins of COVID-19.

Thank you again for the opportunity to join this letter. We wish you the very best.

Sincerely,

Ann C. Agnew
Executive Secretary



202005717
United States Department of State

Washington, D.C. 20520

www.state.gov

May 15, 2020

SENSITIVE BUT UNCLASSIFIED

MEMORANDUM FOR MS. ANNE C. AGNEW
EXECUTIVE SECRETARY
DEPARTMENT OF HEALTH AND HUMAN SERVICES

SUBJECT: (SBU) Request for Access to Wuhan for International Scientists and
Public Health Experts

(SBU) The Secretary of State intends to send a letter to officials of the People's Republic of China (PRC) requesting that the PRC authorize and facilitate a visit of international scientists and public health experts to Wuhan to exchange information with counterparts who have conducted research on coronaviruses (including the origin and characteristics of SARS-CoV-2), examine all relevant data, and visit laboratory facilities where such work has been conducted, including the Wuhan Institute of Virology and the Wuhan Center for Disease Control and Prevention laboratories. The purpose of the visit would be to access critical information needed to fight the COVID-19 pandemic and to prevent future outbreaks.

(SBU) The Department of State hereby respectfully invites the Secretary of Health and Human Services to co-sign a letter to PRC Executive Vice Premier Han Zheng and Yang Jiechi, Director of the Office of Foreign Affairs of the Communist Party of China. A draft of the letter is enclosed with this memorandum. The Department of State is separately requesting OSTP Director Droege meier co-sign the letter as well.

(b)(6)

Lisa D. Kenna
Executive Secretary

Attachment:

Letter to Executive Vice Premier Han and Director Yang

SENSITIVE BUT UNCLASSIFIED

His Excellency Han Zheng
Vice Premier
of the People's Republic of China
Beijing

His Excellency Yang Jiechi
Director of the Office of Foreign Affairs
of the Communist Party of China
Beijing

Dear Vice Premier Han and Director Yang:

(b)(5)

Sincerely,

Michael R. Pompeo

From: Marks, Peter [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DFBB2B5BD38445CB9C9ADCA3F72DF53A-MARKSP]
Sent: 6/3/2020 8:26:51 AM
To: McNeill, Lorrie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=77b0b352c9c24851bf0c7330f53e00d9-McNeill]
CC: Tierney, Julia [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1160d300bc4248b790ded292a082e9a8-Julia.Tiern]
Subject: RE: See this instead

Dear Lorrie,

Thanks!

Best Regards,
Peter

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Sent: Tuesday, June 2, 2020 12:33 PM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>
Cc: Tierney, Julia <Julia.Tierney@fda.hhs.gov>
Subject: FW: See this instead

Hi Peter –

Karen Riley in OGDG shared the email string below and attachments regarding a letter to the Department of State declining to co-sign a letter to the PRC. The attached draft response notes that HHS has already sent a letter to the Secretary's counterpart and therefore do not want to "confuse issues" by joining this letter.

After Karen sent, she sent a separate note that Mark Abdoos has cleared the draft and at this point it's an FYI only for us (despite the note below that you should review).

Lorrie

From: Riley, Karen <Karen.Riley@fda.hhs.gov>
Sent: Tuesday, June 2, 2020 11:07 AM
To: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Subject: See this instead

Hi Lorrie, Somehow the email didn't finish. FDA has been asked to weigh in on an HHS/OGA letter to State declining to sign onto a letter to the Wuhan Institute of Virology. We're thinking that Peter should review. Thanks.

From: Riley, Karen
Sent: Tuesday, June 2, 2020 11:05 AM
To: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Subject: Please see

Hi Lorrie, FDA has been asked to weigh in in an HHS/OGA letter to State declining to sign onto a partiWe

From: Riley, Karen
Sent: Tuesday, June 2, 2020 10:37 AM
To: Hashemi, Sema <Sema.Hashemi@fda.hhs.gov>; Ross, Bruce <Bruce.Ross@fda.hhs.gov>; Anderson, Erika

<Erika.Anderson@fda.hhs.gov>

Subject: Please see

I believe I forwarded this to some of you on Friday. My apologies, I misinterpreted this. I thought it was an FYI, but apparently we are being asked to clear the Agnew letter back to State. Should Janet Woodcock also read and clear?

From: Duarte, Christina <Christina.Duarte@fda.hhs.gov>

Sent: Friday, May 29, 2020 12:49 PM

To: Riley, Karen <Karen.Riley@fda.hhs.gov>

Subject: FW: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Here you go...

From: Duarte, Christina

Sent: Friday, May 29, 2020 12:00 PM

To: Riley, Karen <Karen.Riley@fda.hhs.gov>

Subject: FW: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Hi Karen,

When time permits, can you please review the attached correspondences and information contained in the AIMS email below? Please let me know the POC to send this to.

Thank you,

Christina Duarte

Management and Program Analyst

Communications Team

Office of Global Diplomacy and Partnerships (OGDP)

Office of Global Policy and Strategy

U.S. Food and Drug Administration

(240) 402-5338 (phone)

Christina.Duarte@fda.hhs.gov

From: aimssystem@fda.hhs.gov <aimssystem@fda.hhs.gov>

Sent: Friday, May 29, 2020 11:24 AM

To: Duarte, Christina <Christina.Duarte@fda.hhs.gov>

Subject: Referral from FDA/OC/OES/ on Correspondence Control # 2020-2504

Note: Do NOT reply directly to this E-mail

A referral has been sent to your office by FDA/OC/OES/ on Correspondence Control # 2020-2504 requesting your assistance. A summary of the referral appears below. If you have any questions, please contact VALERIE A. JACKSON WATSON of FDA/OC/OES/.

Action:

Due Date:

Synopsis:

Review and Clear

Tuesday, June 2, 2020

Department R/C -

Request for Access to

Wuhan for International

**Scientists and Public
Health Experts**

Please click the URL below to access the referral:

http://aims.fda.gov/cktoken/ct_token.mainPage?p_token=nrtd6ce3w03d68g9s1z00000vem3vx00001mbksjacetw8324196doqt1z0fnsxs

You can view the original correspondence by clicking the button 'View Orig Corr' (if available). After reviewing all the information provided, please acknowledge receipt of the referral by clicking either the ACCEPT button or the DECLINE button.

If you ACCEPT the referral, a new COMPLETE button is immediately displayed. You can either:

Click the COMPLETE button to complete the referral now

OR

You MUST retain this e-mail with the above URL until you have completed the referral request. Click the above URL again and click the COMPLETE button.

From: Marks, Peter [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DFBB2B5BD38445CB9C9ADCA3F72DF53A-MARKSP]
Sent: 2/12/2021 1:02:05 PM
To: Blair, Joan W. (CBER) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8cc3d088be164491a76b9ce048d71a02-BLAIR]
Subject: RE: additional reporting cable from WHO/Geneva - All COVID-19 origin hypotheses open

Dear Joan,

Thanks so much for forwarding. Wow.

Best Regards,
Peter

From: Blair, Joan W. (CBER) <Joan.Blair@fda.hhs.gov>
Sent: Friday, February 12, 2021 10:05 AM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>
Subject: FW: additional reporting cable from WHO/Geneva - All COVID-19 origin hypotheses open

See final paragraph/comments

From: Ross, Bruce <Bruce.Ross@fda.hhs.gov>
Sent: Friday, February 12, 2021 10:00 AM
To: Abdoo, Mark <Mark.Abdoo@fda.hhs.gov>; 2019-nCoV FDA IMG Leadership: (b)(6) <(b)(6)@fda.hhs.gov>; OGPS OGO Managers/Supervisors: (b)(6) <(b)(6)@fda.hhs.gov>; Anderson, Erika <Erika.Anderson@fda.hhs.gov>
Cc: Torres, Melissa A <Melissa.Torres@fda.hhs.gov>; Mullin, Theresa <Theresa.Mullin@fda.hhs.gov>; Blair, Joan W. (CBER) <Joan.Blair@fda.hhs.gov>; Oehlsen, Michael <Michael.Oehlsen@fda.hhs.gov>; Moss, Julie <Julie.Moss@fda.hhs.gov>; ORA ACRA EAC <oraacraeac@fda.hhs.gov>; Yiannas, Frank <Frank.Yiannas@fda.hhs.gov>; Mayne, Susan <Susan.Mayne@fda.hhs.gov>; Prater, Donald <Donald.Prater@fda.hhs.gov>; Moss, Julie <Julie.Moss@fda.hhs.gov>
Subject: additional reporting cable from WHO/Geneva - All COVID-19 origin hypotheses open

The attached cable is a follow-on to the original reporting cable on WHO's Team's recent in-country visit (shared previously and remaining below).

Bruce

Bruce Ross, MA, MPH
Director

Office of Global Operations
Office of Global Policy and Strategy

COVID-19 Outbreak Response, FDA IMG Logistics – Repatriation

Tel: 240-402-2866
Mobile: (b)(6)
E-mail: Bruce.Ross@fda.hhs.gov